Blistering Breakthroughs: Dupilumab’s Big Debut

Welcome to another episode of Derms on Drugs, where we peel back the layers on the latest in dermatology therapeutics. Today, we’re thrilled to have Dr. Donna Culton join us for a deep dive into the world of bullous pemphigoidIn this episode we:Review three of the hottest papers on bullous pemphigoid, dissecting the latest evidence with our signature blend of rigor and irreverence.Break down the recent FDA approval of dupilumab for bullous pemphigoid—a new kid on the blister block!Unpack the pivotal dupilumab study results, then pit them against real-world evidence. Does the hype hold up outside the ivory tower?Debate how we’ll actually integrate dupilumab into our clinical arsenal. Is this a game-changer or just another tool in the kit?Explore the real impact on patient care: Will this approval mean fewer steroids, better outcomes, or simply more options for those tough-to-treat cases?Refresher course in bullous pemphigoid - diagnosis and practical treatment pearlsSo, whether you’re a seasoned derm or just here for the laughs, tune in as we blister through the data and get under the skin of bullous pemphigoid’s newest treatment frontier.For Links to articles please go to ScholarsinMedicine.com1. Bullous pemphigoid: A practical approach to diagnosis and management in the modern era2. Effectiveness of Dupilumab and Omalizumab in Bullous Pemphigoid: A Nationwide Retrospective Cohort Study3. Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT